Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces stomach acid production.
## Primary Indications
* Erosive esophagitis associated with gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
## Adult Dosing
* **Healing of erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily.
* **GERD symptoms:** 20 mg orally once daily.
* **Pathological hypersecretory conditions:** Starting dose 40 mg orally or intravenously twice daily. Doses may be increased up to 240 mg daily.
## Pediatric Dosing
* **Erosive esophagitis (ages 5 to 16 years):** 40 mg orally once daily for up to 4 weeks.
* **GERD symptoms (ages 5 to 16 years):** 20 mg orally once daily for up to 8 weeks.
* **Note:** Dosing in younger children or for other indications is not well established.
## Dose Adjustments
* **Hepatic Impairment:** Maximum daily dose of 40 mg orally once daily.
## Contraindications
* Known hypersensitivity to pantoprazole or other benzimidazole derivatives.
## Adverse Effects
* Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
* Serious: *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia, vitamin B12 deficiency, lupus erythematosus (cutaneous and systemic).
## Key Drug Interactions
* **Certain Antiretrovirals (e.g., rilpivirine, atazanavir):** Pantoprazole can decrease their absorption. Avoid coadministration or monitor closely.
* **Methotrexate:** PPIs may increase methotrexate levels. Consider temporarily discontinuing pantoprazole during high-dose methotrexate therapy.
* **CYP2C19 substrates (e.g., clopidogrel):** Pantoprazole may alter the metabolism of these drugs.
## Monitoring
* For prolonged use (>3 years): Monitor for vitamin B12 deficiency and hypomagnesemia.
* Monitor for signs/symptoms of *C. difficile*-associated diarrhea.
* Consider bone mineral density monitoring in patients at risk for osteoporosis.
## Clinical Pearls
* Administer orally before a meal.
* Intravenous administration requires reconstitution and dilution.
* Long-term use is associated with potential adverse effects. Reassess the need for therapy periodically.
***
*This information is intended for clinical professionals. Always consult the most current prescribing information and relevant guidelines before making treatment decisions.*
